Long-term safety was stable without emergent signals; grade ≥3 TRAEs stayed ~57–59%, while cumulative neuropathy increased with duration, managed via interruptions and EV dose reductions. Notably, ...

Bicycle Therapeutics trades below net cash, reflecting market skepticism on future cash burn and delayed commercialization.

Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC trial show 71% (5/7) patients resected following ...

A major international study has found that long-term exposure to arsenic may increase the risk of developing several types of urologic cancers. Researchers say the findings highlight the need for ...

Early report on modular BioVAT patches in advanced stage C or D disease ...

US FDA approves AstraZeneca’s Imfinzi for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer: Cambridge, UK Saturday, May 30, 2026, 13:00 Hrs [IST] AstraZene ...

Exposure to arsenic, cadmium and vanadium is linked to increased urologic cancer risk in a major meta-analysis. Read more on ...

Finally, current quality-of-life tools do not fully capture the patient experience. Emerging approaches incorporating patient ...

The EMA has backed new and expanded uses for multiple cancer drugs, signaling a push toward biomarker-driven, earlier-line ...

Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision ...

Nebraska's highest court upheld the denial of workers' compensation death benefits to a widow who claimed her husband's ...

AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...